Presentation is loading. Please wait.

Presentation is loading. Please wait.

Progastrin expression in colonic tissues and Kaplan–Meier survival curves. Progastrin expression in colonic tissues and Kaplan–Meier survival curves. A,

Published bySamantha French Modified over 5 years ago

Similar presentations

Presentation on theme: "Progastrin expression in colonic tissues and Kaplan–Meier survival curves. Progastrin expression in colonic tissues and Kaplan–Meier survival curves. A,"— Presentation transcript:

1 Progastrin expression in colonic tissues and Kaplan–Meier survival curves.
Progastrin expression in colonic tissues and Kaplan–Meier survival curves. A, percentage of progastrin-positive cells for normal colon, hyperplastic polyps (HP), low-grade dysplasia tubular adenoma (TA), high-grade dysplasia TA, and adenocarcinoma (ADC). Wilcoxon tests were conducted to compare the percentage of progastrin-positive cells in the different tissues with the percentage in normal colon. B, overall NFS among patients with a colonoscopic follow-up. C, NFS among patients with a colonoscopic follow-up, according to progastrin staining. P value corresponds to log-rank univariate analysis. Catherine Do et al. Cancer Prev Res 2012;5: ©2012 by American Association for Cancer Research

Download ppt "Progastrin expression in colonic tissues and Kaplan–Meier survival curves. Progastrin expression in colonic tissues and Kaplan–Meier survival curves. A,"

Similar presentations

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.

Frequency of JAK1 and JAK2 alterations and their association with overall survival in TCGA datasets. Frequency of JAK1 and JAK2 alterations and their association.
Prognostic significance of DDB2 in ovarian cancer.

Prognostic significance of DDB2 in ovarian cancer.
25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.

25(OH)D and 1,25(OH)2D perfusion treatment effect on cancer-related markers: IF stains illustrating expression levels for Ki-67 (A), cyclin D1 (B), ErbB-2.
Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.

Kaplan–Meier curves of 12-month survival after an index chronic obstructive pulmonary disease-related hospitalisation according to level of moderate and.
Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.
Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.
A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)

A–d) Comparison of Kaplan–Meier curves of a) progression-free survival (PFS) and c) overall survival (OS) in large-cell neuroendocrine carcinoma (LCNEC)
miRNA expression patterns in stools from healthy subjects.

miRNA expression patterns in stools from healthy subjects.
This month in Gastroenterology

This month in Gastroenterology
AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,

AR signaling in CTCs from CRPC patients treated with abiraterone acetate. AR signaling in CTCs from CRPC patients treated with abiraterone acetate. A,
Volume 123, Issue 5, Pages (November 2002)

Volume 123, Issue 5, Pages (November 2002)
Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.
Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.

Kaplan–Meier survival curves of all-cause mortality in patients with idiopathic pulmonary fibrosis (IPF). Kaplan–Meier survival curves of all-cause mortality.
Histologic characterization of ACF, and the effects of tocopherol treatment on ACF formation, 4-HNE levels, and nitrotyrosine levels in the colon. Histologic.

Histologic characterization of ACF, and the effects of tocopherol treatment on ACF formation, 4-HNE levels, and nitrotyrosine levels in the colon. Histologic.
NICD1 immunohistochemical staining in normal and tumor tissue.

NICD1 immunohistochemical staining in normal and tumor tissue.
Kaplan–Meier curves for the time until development of microscopic polyangiitis (MPA) (A) and for survival (B) in myeroperoxidase-antineutrophil cytoplasmic.

Kaplan–Meier curves for the time until development of microscopic polyangiitis (MPA) (A) and for survival (B) in myeroperoxidase-antineutrophil cytoplasmic.
Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.
Expression of cGMP signaling components in polyps.

Expression of cGMP signaling components in polyps.
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
A, SSA/P is seen in the right colon (outlined by arrows) at colonoscopy. A, SSA/P is seen in the right colon (outlined by arrows) at colonoscopy. Note.

A, SSA/P is seen in the right colon (outlined by arrows) at colonoscopy. A, SSA/P is seen in the right colon (outlined by arrows) at colonoscopy. Note.

Similar presentations

Ads by Google